Non-expression of a common mutation in the 21-hydroxylase gene: implications for prenatal diagnosis and carrier testing

G Rumsby, A F Massoud, C Avey, C G D Brook

Abstract
Mutation analysis in the family of a child with 21-hydroxylase deficiency showed that the father and affected child were homozygous for a mutation, A/C655G, believed to activate a cryptic splice site in intron 2 of the 21-hydroxylase gene. The father, who was clinically asymptomatic, showed no biochemical evidence of disease. These results create problems for the management of future pregnancies in such families and for the interpretation of the risk associated with carrier status for this mutation.

(J Med Genet 1996;33:798–799)

Key words: 21-hydroxylase; mutation; non-expression.

Deficiency of the steroid 21-hydroxylase (CYP21) enzyme is the most frequent cause of congenital adrenal hyperplasia (CAH). It is characterised by glucocorticoid and mineralocorticoid insufficiency leading to salt loss in the neonatal period, and increased synthesis of adrenal androgens leading to virilisation of the female fetus in utero and to precocious puberty in undiagnosed males.

The gene, CYP21, is located on chromosome 6p within the HLA class III region. More than 95% of mutations are the result of either recombination with a pseudogene some 30 kilobases (kb) upstream leading to gross deletions at the locus or smaller gene conversions in which part of the CYP21 sequence is replaced by that of the pseudogene, CYP21P. The mutations are so frequent that they can be used as part of a diagnostic repertoire for prenatal diagnosis and carrier testing for the disease.1,3

One mutation in the second intron occurs at a polymorphic site such that either adenosine or cytosine is replaced by guanine at nucleotide 655 and is believed to influence the activation of a cryptic splice site some 19 nucleotides upstream of exon 3.4 The mutation is relatively common, occurring on approximately 34% of alleles in our series of 90 patients (G Rumsby, unpublished data) and from 17 to 32% in other published reports.5 The mutation profile of a family presenting for prenatal diagnosis of CAH showed that one of the parents was homozygous for this mutation. Here we report the investigation of this family and discuss the implications for prenatal diagnosis of this disease.
Non-expression of a common mutation in the 21-hydroxylase gene

Samples from subjects lacking either CYP21 or CYP21P were used as controls.\(^8\) Sequence analysis of two clones containing the paternal CYP21 intron 2 confirmed the presence of the A/C655G mutation and the T453C polymorphism in addition to a C to A change at nucleotide 419. In view of the father’s genotype the following biochemical investigations were performed: Na\(^+\) 141 mmol/l, K\(^+\) 4.4 mmol/l, urea 7 mmol/l, serum cortisol 381 nmol/l, plasma aldosterone (recumbent) 312 pmol/l (100-500), plasma renin activity (PRA) (recumbent) 3.25 pmol/ml/h (1.14-2.65). A urine steroid profile showed raised pregnanetriol (1560 \(\mu\)g/day; normal for adult males: 110-520). Following synaethen stimulation (250 \(\mu\)g intravenous bolus) serum 17-hydroxyprogesterone rose from a basal level of 2.9 nmol/l to 8.1 nmol/l at 60 minutes (normal <20 nmol/l). These investigations excluded a diagnosis of CAH despite his homoygous genotype.

Mutation analysis is the most accurate form of genetic diagnosis as it predicts the actual sequence change causing the disease and is therefore less susceptible to error through recombination. However, here we describe a family in whom one of the parents is homozygous for a known deleterious mutation but clinically asymptomatic and biochemically normal except for a slightly raised urinary pregnanetriol and mildly raised PRA. Such a situation has been recently described\(^{10}\) but no satisfactory explanation was presented.

The association of the A/C655G mutation with activation of a cryptic splice site has been described in vitro\(^{11,12}\) and in vivo (C Avey, G Ramsby, G Conway, manuscript in preparation). Mutations which affect splicing are known to be leaky,\(^{12}\) the cell making a certain amount of normally spliced mRNA, and one could therefore hypothesise that the mutation is variably expressed. Such an explanation may help in part to account for the inexact relation between genotype and phenotype in CYP21 deficiency.\(^{13}\) As no additional homozygotes were available for study in this particular family, it is not possible to know whether such variation can occur within a family. A second possibility is that the A/C655G mutation may occur in the presence of an additional sequence change in either the intron or neighbouring exon, which negates the influence of the mutation on the cryptic splice site. The sequence data obtained in the present study did not, however, identify any additional pathological sequence changes in this region. This subject was, however, homozygous for five polymorphisms in the intron 2/exon 3 region and it was therefore not possible to claim with certainty that both alleles were sequenced. Lastly, 655G may simply be in association with another mutation, although this proposal is unlikely in view of the expression studies discussed above.

Family studies on patients with CYP21 deficiency have identified subjects who had not presented clinically although were found to have the disease on biochemical testing (cryptic CAH). Genetic analysis as described in this manuscript has now also identified people homozygous for disease mutations but who are clinically asymptomatic and show only minor biochemical abnormalities. The problem for the doctor is the management of the family. It would seem justified to test all homozygotes for the mutation for their response to synaethen stimulation to exclude cryptic CAH. If there is no response or one indicating carrier status alone, can prenatal diagnosis be offered using linkage analysis to differentiate between the two alleles? The alternative is to offer prenatal treatment of the pregnancy with dexamethasone to term in the case of a female homozygous for the mutation. Biochemical testing after birth in both males and females will then confirm their disease status.

It is simply not known at this time whether the asymptomatic homozygotes for the splice site mutation will go on to develop the disease later in life. Until more is known about what makes this mutation deleterious to CAH, it poses major difficulties for genetic counselling of these families and carriers of such a mutation.